---
title: "sh-Oligopeptide-1 (Human EGF)"
canonical_url: https://peptidelibrary.app/library/egf-oligopeptide-1
description: "Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# sh-Oligopeptide-1 (Human EGF)

sh-Oligopeptide-1 (Human EGF), also called rh-EGF or Epidermal growth factor (cosmetic), is a research peptide in the Growth-factor mimetic class. Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling.

Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.

Also known as: rh-EGF, Epidermal growth factor (cosmetic).

Categories: Cosmetic, Experimental.

## Classification

- Type: Cosmetic EGF / research
- Mechanism class: Growth-factor mimetic
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations. The practical constraint is delivery: at roughly 6 kDa the intact protein is far above the size that passively crosses an intact stratum corneum, so meaningful penetration depends on formulation, carriers, or compromised barrier function. Claims about topical activity should be read against that limitation.

Targets: EGFR.

Origin: Recombinant EGF or cosmetic oligopeptide listing.

## Properties

- Molecular formula: C270H401N73O83S7
- Molecular weight: ≈6.2 kDa (protein growth factor)
- CAS number: 62253-63-8
- Half-life: Topical; systemic PK not applicable
- Studied routes: Topical

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Abud B et al. A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception. J Cosmet Dermatol. 2026. 2026. Controlled human trial. Population: 20 women aged 50–65 with moderate to severe facial photoageing. Investigator ratings of texture and firmness favoured the oligopeptide-1 serum at later visits; wrinkle severity changed little in either group [Source](https://pubmed.ncbi.nlm.nih.gov/42152512/)
2. Martínez-Carpio PA. Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? Cutan Ocul Toxicol. 2023. 2023. Secondary report (review or programme summary), not a trial. Population: 12 articles, 9 of them clinical trials that used sh-oligopeptide-1 as if it were recombinant human EGF. The author concludes that the preclinical bioactivity of sh-oligopeptide-1 has not been proven, that it is not a functional EGF, and that topical recombinant human EGF is not authorised as a medicine except in clinical trials. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/37452558/)

## Safety

Side effects: Irritation; Theoretical EGFR stimulation concerns.

Risks: Cosmetic grade is not a drug.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

sh-Oligopeptide-1 (Human EGF) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is sh-Oligopeptide-1 (Human EGF)?

Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.

### How does sh-Oligopeptide-1 (Human EGF) work?

Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations.

### Is sh-Oligopeptide-1 (Human EGF) FDA approved?

No. sh-Oligopeptide-1 (Human EGF) is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of sh-Oligopeptide-1 (Human EGF)?

Reported half-life for sh-Oligopeptide-1 (Human EGF) is Topical; systemic PK not applicable. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is sh-Oligopeptide-1 (Human EGF) banned in sport?

sh-Oligopeptide-1 (Human EGF) is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to sh-Oligopeptide-1 (Human EGF)?

Compounds most often compared with sh-Oligopeptide-1 (Human EGF) include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception — J Cosmet Dermatol, 2026](https://pubmed.ncbi.nlm.nih.gov/42152512/)
- [Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? — Cutan Ocul Toxicol, 2023](https://pubmed.ncbi.nlm.nih.gov/37452558/)
